Lantheus Holdings, Inc. is a leading radiopharmaceutical company that develops, manufactures, and commercializes innovative diagnostic and therapeutic products to assist clinicians in the diagnosis and treatment of heart, cancer, and other critical diseases. The company operates through three primary business segments: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. The Radiopharmaceutical Oncology segment is driven by its flagship product, PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer, which accounts for approximately 70% of the company's total revenue. The Precision Diagnostics segment features DEFINITY, a widely utilized injectable ultrasound enhancing agent for echocardiography exams. Additionally, Lantheus engages in strategic partnerships to advance precision medicine through biomarkers and digital solutions. The company markets its products primarily to hospitals, independent imaging centers, and government facilities across the United States, while also distributing internationally in Europe, Canada, Australia, and other regions through direct and third-party relationships. By focusing on high-growth radiopharmaceutical and therapeutic segments, Lantheus maintains a strong competitive position in the medical imaging and precision diagnostics markets.
